Supplementation with the Sialic Acid Precursor N-acetyl-D-Mannosamine Breaks the Link Between Obesity and Hypertension.

Background: Obesity-related hypertension is a common disorder, and attempts to combat the underlying obesity are often unsuccessful. We previously revealed that mice globally deficient in the inhibitory IgG receptor FcγRIIB are protected from obesity-induced hypertension. However, how FcγRIIB participates is unknown. Studies were designed to determine if alterations in IgG contribute to the pathogenesis of obesity-induced hypertension. Methods: Involvement of IgG was studied using IgG μ heavy chain-null mice deficient in mature B cells, and by IgG transfer. Participation of FcγRIIB was interrogated in mice with global or endothelial cell-specific deletion of the receptor. Obesity was induced by high fat diet (HFD) and BP was measured by radiotelemetry or tail cuff. The relative sialylation of the Fc glycan on mouse IgG, which influences IgG activation of Fc receptors, was evaluated by SNAlectin blotting. Effects of IgG on endothelial NO synthase (eNOS) were assessed in human aortic endothelial cells. IgG Fc glycan sialylation was interrogated in 3442 human subjects by mass spectrometry, and the relationship between sialylation and BP was evaluated. Effects of normalizing IgG sialylation were determined in HFD-fed mice administered the sialic acid precursor N-acetyl-D-mannosamine (ManNAc). Results: Mice deficient in B cells were protected from obesity-induced hypertension. Compared to IgG from control chow-fed mice, IgG from HFD-fed mice was hyposialylated, and it raised BP when transferred to recipients lacking IgG; the hypertensive response was absent if recipients were FcγRIIB-deficient. Neuraminidase (NA)-treated IgG lacking the Fc glycan terminal sialic acid also raised BP. In cultured endothelial cells, via FcγRIIB, IgG from HFD-fed mice and NAtreated IgG inhibited VEGF activation of eNOS by altering eNOS phosphorylation. In humans obesity was associated with lower IgG sialylation, and systolic BP was inversely related to IgG sialylation. Mice deficient in FcγRIIB in endothelium were protected from obesity-induced hypertension. Furthermore, in HFD-fed mice, ManNAc normalized IgG sialylation and prevented obesity-induced hypertension. Conclusions: Hyposialylated IgG and FcγRIIB in endothelium are critically involved in obesityinduced hypertension in mice, and supportive evidence was obtained in humans. Interventions targeting these mechanisms, such as ManNAc supplementation, may provide novel means to break the link between obesity and hypertension.

[1]  W. Wang,et al.  The association between subclass-specific IgG Fc N-glycosylation profiles and hypertension in the Uygur, Kazak, Kirgiz, and Tajik populations , 2018, Journal of Human Hypertension.

[2]  R. Touyz,et al.  Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events , 2018, Journal of the American Society of Hypertension : JASH.

[3]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association , 2018, Circulation.

[4]  Debabrata Ghosh,et al.  Hyposialylated IgG activates endothelial IgG receptor Fc&ggr;RIIB to promote obesity-induced insulin resistance , 2017, The Journal of clinical investigation.

[5]  Fabian J Theis,et al.  Network inference from glycoproteomics data reveals new reactions in the IgG glycosylation pathway , 2017, Nature Communications.

[6]  Youxin Wang,et al.  Immunoglobulin G N-Glycans as Potential Postgenomic Biomarkers for Hypertension in the Kazakh Population. , 2017, Omics : a journal of integrative biology.

[7]  Ann M. Stowe,et al.  Heterogeneity of B Cell Functions in Stroke-Related Risk, Prevention, Injury, and Repair , 2016, Neurotherapeutics.

[8]  D. Atochin,et al.  Endothelial Fcγ Receptor IIB Activation Blunts Insulin Delivery to Skeletal Muscle to Cause Insulin Resistance in Mice , 2016, Diabetes.

[9]  I. Rudan,et al.  The Association Between Glycosylation of Immunoglobulin G and Hypertension , 2016, Medicine.

[10]  K. Peter,et al.  Obligatory Role for B Cells in the Development of Angiotensin II–Dependent Hypertension , 2015, Hypertension.

[11]  Michael E. Hall,et al.  Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. , 2015, Circulation research.

[12]  C. Mineo,et al.  IgG Receptor Fc&ggr;RIIB Plays a Key Role in Obesity-Induced Hypertension , 2015, Hypertension.

[13]  A. Khera,et al.  Fc&ggr; Receptors and Ligands and Cardiovascular Disease , 2015, Circulation research.

[14]  I. Nishino,et al.  GNE myopathy: current update and future therapy , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  C. Sobey,et al.  Antibodies in the Pathogenesis of Hypertension , 2014, BioMed research international.

[16]  O. Ohara,et al.  Obesity-associated autoantibody production requires AIM to retain the immunoglobulin M immune complex on follicular dendritic cells. , 2013, Cell reports.

[17]  D. Atochin,et al.  C-Reactive Protein Causes Insulin Resistance in Mice Through Fcγ Receptor IIB–Mediated Inhibition of Skeletal Muscle Glucose Delivery , 2013, Diabetes.

[18]  L. Igel,et al.  Obesity‐related hypertension: Pathogenesis, cardiovascular risk, and treatment—A position paper of the The Obesity Society and the American Society of Hypertension , 2013, Obesity.

[19]  L. Igel,et al.  Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment , 2013, Journal of clinical hypertension.

[20]  P. Bruhns Properties of mouse and human IgG receptors and their contribution to disease models. , 2012, Blood.

[21]  J. Ravetch,et al.  Novel roles for the IgG Fc glycan , 2012, Annals of the New York Academy of Sciences.

[22]  R. Iliescu,et al.  Systemic and Renal-Specific Sympathoinhibition in Obesity Hypertension , 2012, Hypertension.

[23]  N. Poulter,et al.  Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk , 2011, Journal of hypertension.

[24]  Michael N. Alonso,et al.  B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies , 2011, Nature Medicine.

[25]  Hyung-Suk Kim,et al.  Lymphocyte responses exacerbate angiotensin II-dependent hypertension. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[26]  T. Michel,et al.  Cellular signaling and NO production , 2010, Pflügers Archiv - European Journal of Physiology.

[27]  E. Coşgun,et al.  Comparison of Early and Late Changes in Immunoglobulins and Acute Phase Reactants after Laparoscopic Adjustable Gastric Banding in Patients with Morbid Obesity , 2010, Obesity surgery.

[28]  M. Quon,et al.  C-Reactive Protein Inhibits Insulin Activation of Endothelial Nitric Oxide Synthase via the Immunoreceptor Tyrosine-Based Inhibition Motif of FcγRIIB and SHIP-1 , 2009, Circulation research.

[29]  F. Gudé,et al.  Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities , 2007, Clinical and experimental immunology.

[30]  D. Harrison,et al.  Role of the T cell in the genesis of angiotensin II–induced hypertension and vascular dysfunction , 2007, The Journal of experimental medicine.

[31]  B. Galeano,et al.  Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. , 2007, The Journal of clinical investigation.

[32]  P. Shaul,et al.  C-Reactive Protein Causes Downregulation of Vascular Angiotensin Subtype 2 Receptors and Systolic Hypertension in Mice , 2007, Circulation.

[33]  Elisabete Pinto Blood pressure and ageing , 2007, Postgraduate Medical Journal.

[34]  K. Midthjell,et al.  Change in body mass index and its impact on blood pressure: a prospective population study , 2005, International Journal of Obesity.

[35]  J. Reckelhoff Gender Differences in the Regulation of Blood Pressure , 2001, Hypertension.

[36]  L. Lanier,et al.  Immune inhibitory receptors. , 2000, Science.

[37]  P. Whelton,et al.  Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. , 1999, American heart journal.

[38]  M. Pepys,et al.  Serum amyloid P-component is an acute-phase reactant in the mouse , 1979, Nature.

[39]  M. Wuhrer,et al.  High-Throughput Analysis of IgG Fc Glycopeptides by LC-MS. , 2017, Methods in molecular biology.